These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 7298112)
21. Evaluation of once daily hydralazine in inadequately controlled hypertension. Danielson M; Kjellberg J; Ohman P; Wernersson B Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of oral hydralazine in chronic heart failure. Hanson A; Johansson BW; Wernersson B; Wåhlander LA Eur J Clin Pharmacol; 1983; 25(4):467-73. PubMed ID: 6653641 [TBL] [Abstract][Full Text] [Related]
23. Effect of dose on acetylator phenotype distribution of hydralazine. Timbrell JA; Harland SJ; Facchini V Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604 [TBL] [Abstract][Full Text] [Related]
25. Acetylation phenotype in hypertensive patients. Huang CY; Chu JY; Yen TC Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Jan; 8(1):1-5. PubMed ID: 1548734 [TBL] [Abstract][Full Text] [Related]
26. Plasma hydrazine concentrations in man after isoniazid and hydralazine administration. Blair IA; Mansilla Tinoco R; Brodie MJ; Clare RA; Dollery CT; Timbrell JA; Beever IA Hum Toxicol; 1985 Mar; 4(2):195-202. PubMed ID: 4007883 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans. Shepherd AM; Ludden TM; Haegele KD; Talseth T; McNay JL Res Commun Chem Pathol Pharmacol; 1979 Oct; 26(1):129-44. PubMed ID: 515498 [TBL] [Abstract][Full Text] [Related]
28. Metabolism of hydralazine in man. Part II: Investigation of features relevant to drug safety. Dubois JP; Schmid K; Riess W; Hanson A; Henningsen NC; Andersson OK Arzneimittelforschung; 1987 Feb; 37(2):189-93. PubMed ID: 3580022 [TBL] [Abstract][Full Text] [Related]
29. Influence of acetylator phenotype and renal function on the antihypertensive effect of hydralazine. Koopmans PP; Hoefnagels WH; Huysmans FT; Thien T Neth J Med; 1984; 27(3):69-73. PubMed ID: 6709112 [No Abstract] [Full Text] [Related]
30. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes. McQueen CA; Maslansky CJ; Glowinski IB; Crescenzi SB; Weber WW; Williams GM Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1269-72. PubMed ID: 6951172 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the acetylation of procainamide and sulfadimidine in man. Frislid K; Berg M; Hansteen V; Lunde PK Eur J Clin Pharmacol; 1976 Mar; 09(5-6):433-8. PubMed ID: 971707 [TBL] [Abstract][Full Text] [Related]
33. Hydrallazine and beta-blockade in refractory hypertension with characterization of acetylator phenotype. Hunyor SN Aust N Z J Med; 1975 Dec; 5(6):530-6. PubMed ID: 7224 [TBL] [Abstract][Full Text] [Related]
34. Relationship of sulfamethazine disposition kinetics to acetylator phenotype in man. A preliminary study. Chapron CJ; Blum MR J Clin Pharmacol; 1976 Jul; 16(7):338-44. PubMed ID: 947966 [TBL] [Abstract][Full Text] [Related]
35. Hydralazine-induced lupus: is there a toxic metabolic pathway? Timbrell JA; Facchini V; Harland SJ; Mansilla-Tinoco R Eur J Clin Pharmacol; 1984; 27(5):555-9. PubMed ID: 6519160 [TBL] [Abstract][Full Text] [Related]
36. Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man. Facchini V; Timbrell JA Br J Clin Pharmacol; 1981 Apr; 11(4):345-51. PubMed ID: 7259927 [TBL] [Abstract][Full Text] [Related]
37. Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype. Harland SJ; Facchini V; Timbrell JA Br Med J; 1980 Jul; 281(6235):273-4. PubMed ID: 7427242 [No Abstract] [Full Text] [Related]